Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion has entered into a joint R&D and licensing agreement with Korean biotech MUSTBIO for the development of a PD-1 x VEGF x IL-2v tri-functional fusion protein novel drug, with a total potential deal value of up to KRW 712.5B.
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Execution of Joint R&D and License Agreement for Novel Drug Development of PD-1 x VEGF x IL-2v Tri-functional Fusion Protein (Major Management Matters)
- Counterparty: MUSTBIO Inc. (Korea)
- Contract / Confirmation Date: October 31, 2025
- Contract Details: Joint R&D and licensing for a tri-functional fusion protein targeting PD-1, VEGF, and IL-2v using MUSTBIO’s proprietary cytokine and multi-specific antibody platforms
- Contract Period: From the execution date until the latest of the expiration date of relevant substance patent rights or 10 years from the first commercial sale
- Contract Values (Total Value: Up to KRW 712.5B):
- Upfront Fee: KRW 3.0B
- Development Milestones: Up to KRW 39.5B (payable upon non-clinical, clinical, and regulatory milestones)
- Commercialization Milestones: Up to KRW 670.0B (payable based on commercial sales benchmarks, assuming net sales reach KRW 10T)
- Royalties: Running royalty of 5% on net sales after product launch
- Investment Caution & Risk Factors:
- Conditional agreement subject to termination if research/development is halted by regulatory authorities or fails to achieve approval
- Development and commercial milestones are conditional upon achieving specific benchmarks (no penalty fees incurred if terminated early)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Joint R&D Progress and Non-Clinical / Clinical Development Advances
This disclosure details Celltrion’s joint R&D and license agreement with MUSTBIO to develop a tri-functional fusion protein novel drug candidate, making it important to monitor initial research milestones and entry into non-clinical/clinical phases. Tracking R&D advances following platform integration ensures verification of project execution. Joint research progress, milestone payments, and clinical updates can be verified through future regulatory disclosures or upcoming periodic filings (Quarterly, Half-Yearly, or Annual Business Reports).
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
